ARTICLE | Company News
Cell Pathways cancer news
November 4, 2002 8:00 AM UTC
To conserve capital, CLPA eliminated its 16-person sales force, halting sales of Nilandron nilutamide for prostate cancer from Aventis S.A. (AVE, Strasbourg, France). The company's promotion agreemen...